A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: HER2 + Breast Cancer, HER2 + Gastric Cancer, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma|HER2 + Breast Cancer|HER2 + Gastric Cancer|Squamous Cell Carcinoma of Head and Neck|Esophageal Squamous Cell Carcinoma
Interventions: DRUG: LJM716
Sponsor: Novartis Pharmaceuticals